Signal from the log
Alveus Therapeutics
197 M$ · Undisclosed · United States · Biotech
Biotech américaine qui développe ALV-100, une thérapie combinant deux signaux métaboliques contre l'obésité, en phase 1b, et ALV-200 qui vise le récepteur de l'amyline, avec une piste orale à l'étude. Elle entre dans une course où les traitements injectables dominent.
Verified
Announced on , logged by the watch of 12 August 2026.
- Operation
- Funding round
- Announced amount
- 197 M$
- Stage
- Undisclosed
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by New Rhein Healthcare Investors , Andera Partners , Omega Funds , with Novo Holdings , Jeito Capital , Sanofi Capital , Kurma Partners , Avego BioScience Capital
Provenance
Source longevity
Logged on 12 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.